|Title:|| Phenidate drug formulations having diminished abuse potential|
|Abstract:||Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.|
|Inventor(s):|| Zeitlin; Andrew L. (Millington, NJ), Dariani; Maghsoud M. (Fanwood, NJ) |
|Assignee:|| Celgene Corporation (Warren, NJ) |
1. A pharmaceutical unit dosage comprising from about 1 to about 50 milligrams of compound having the formula: ##STR4##
or a pharmaceutically acceptable salt thereof, wherein R.sub.1 is C.sub.1 -C.sub.4 alkyl, and R.sub.2 is hydrogen or C.sub.1 -C.sub.4 alkyl, in a pharmaceutically acceptable carrier or diluent, said dosage form having less than 10% by weight of
other stereoisomers of the compound or salt.
2. The unit dosage of claim 1 comprising from about 2 to about 20 milligrams of said compound.
3. The unit dosage of claim 1 comprising from about 21/2 to about 12 milligrams of said compound.
4. The unit dosage of claim 1 in a form suitable for oral administration.